Drugmaker AbbVie stole the spotlight last week following its maiden voyage on the NYSE, but it's biotech Gilead -- AbbVie's chief rival in the hepatitis-C space -- that's taking a bow today.
Gilead is presenting at the J.P. Morgan Global Healthcare Conference and offered a preview showing that its experimental hepatitis-C drugs are marching steadily through phase 2 and 3 trials. In this video, health care analyst Max Macaluso runs down this news and explains what led to Gilead's modest 1.5% pop today.
What's inside Supernova?
If you're an investor looking for big long-term winners, Motley Fool co-founder David Gardner's picks have frequently trounced the market. How? Because he's always on the lookout for revolutionary stocks and recommends them before Wall Street catches on to their disruptive potential. If you're interested in how David discovers his winners, click here to get instant access to a personal tour behind David's Supernova service.
The article Will This Biotech Dominate the Hepatitis-C Market? originally appeared on Fool.com.
Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool recommends Gilead Sciences and Vertex Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.